A cell-targeted prodrug was developed for the anti-cancer drug Taxol, using
hyaluronic acid (HA) as the drug carrier. HA-Taxol bioconjugates were synt
hesized by linking the Taxol 2'-OH via a succinate ester to adipic dihydraz
ide-modified HA (HA-ADH). The coupling of Taxol-NHS ester and HA-ADH provid
ed several HA bioconjugates with different levels of ADH modification and d
ifferent Taxol loadings. A fluorescent BODIPY-HA was also synthesized to il
lustrate cell targeting and uptake of chemically modified HA using confocal
microscopy. HA-Taxol conjugates showed selective toxicity toward the human
cancer cell lines (breast, colon, and ovarian) that are known to overexpre
ss HA. receptors, while no toxicity was observed toward a mouse fibroblast
cell line at the same concentrations used with the cancer cells. The drug c
arrier HA-ADH was completely nontoxic. The selective cytotoxicity is consis
tent with the results from confocal microscopy, which demonstrated that BOD
IPY-HA only entered the cancer cell lines.